Overview
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Eligibility
Inclusion Criteria:
- Age ≥ 18 years
- Scalp biopsy consistent with LPP
- Active and symptomatic LPP at screening and baseline-
- Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2
Exclusion Criteria:
- History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
- High risk of thrombosis or cardiovascular disease
- High risk of herpes zoster
- Active or recent infection


